Pharmaceuticals, Biotechnology and Life Sciences
Cell Therapy Ltd will begin the application process for a conditional marketing authorisation (CMA) for Heartcel, the first allogeneic stem cell therapy to regenerate the human heart, in Europe.
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, intends to join the AIM market of the London Stock Exchange by way of a Placing to raise approximately £5 million.
FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.
Novartis’s Alcon has received US Food and Drug Administration (FDA) approval for its AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery.
accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC)
Vectura’s partner on the VR876 programme has achieved an important development milestone in Europe, which triggered a cash milestone payment of €5m (circa. £3.6m) to Vectura.
Pfizer Inc. has announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
Vernalis plc has announces that it has acquired the US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (“Pragma”).
Novartis company has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.